Literature DB >> 23211294

Is the presence of 6 or fewer crypt apoptotic bodies sufficient for diagnosis of graft versus host disease? A decade of experience at a single institution.

Jingmei Lin1, Rong Fan, Zijin Zhao, Oscar W Cummings, Shaoxiong Chen.   

Abstract

Histopathology assessment is crucial for the diagnosis of graft versus host disease (GVHD), as the presence of crypt apoptosis is the cardinal criterion required. However, crypt apoptosis is not limited to GVHD; it also occurs in other conditions such as infection, drug reaction, or inflammatory reactions unrelated to GVHD. To better determine whether the presence of 6 or fewer apoptotic bodies is sufficient for the diagnosis of GVHD, we retrospectively reviewed 78 colon biopsies from 66 patients who received either hematopoietic stem cell (HSCT) or cord blood cell transplantation and whose colon biopsies exhibited apoptotic bodies. Among them, 41 cases contained 6 or fewer apoptotic bodies in the colon biopsy. These biopsies were compared with 141 colon biopsy controls that showed no significant pathologic changes as well as 16 colon biopsies with cytomegalovirus colitis from patients without a history of bone marrow transplantation. Among the 41 cases reviewed, 7 patients had coexisting GVHD in other organs (skin or liver). However, gastrointestinal symptoms of at least 4 HSCT patients whose colon biopsies contained 6 or fewer apoptotic bodies completely resolved in the absence of further intervention for GVHD. The discrepancy between pathologic findings and the clinical course may be due to confounding factors, such as infection or medication-induced injury. Our data suggest that identifying 6 or fewer crypt apoptotic bodies in colon biopsies from HSCT patients is worth reporting in order to alert the clinicians of the possibility of GVHD but not sufficient to render a diagnosis on the pathologic grounds alone. The colon biopsies containing 6 or fewer apoptotic bodies represent a heterogenous group. We suggest this group to be classified as indeterminate for GVHD, instead of diagnosing GVHD outright. Synthesis of all clinical, endoscopic, and pathologic information, including the status of infection, coexisting GVHD involvement in the other organs, and medication, is essential for confirmation of the diagnosis of GVHD.

Entities:  

Mesh:

Year:  2013        PMID: 23211294     DOI: 10.1097/PAS.0b013e318272c62a

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

Review 1.  Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Authors:  Steven Naymagon; Leonard Naymagon; Serre-Yu Wong; Huaibin Mabel Ko; Anne Renteria; John Levine; Jean-Frederic Colombel; James Ferrara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

2.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

3.  Histologic analysis has a prognostical value in colorectal biopsies assessed for suspicion of graft-versus-host disease.

Authors:  Fanny Sauvestre; Geneviève Belleannée; Claire Bréal; Catherine Mohr; Harold IpKan Fong; Sébastien Cossin; Reza Tabrizi; Noël Milpied; Stéphane Vigouroux; Jean-François Goussot; Marion Marty
Journal:  Virchows Arch       Date:  2017-11-22       Impact factor: 4.064

4.  Graft-versus-Host Disease of the Gut: A Histologic Activity Grading System and Validation.

Authors:  David Myerson; Gideon Steinbach; Ted A Gooley; Howard M Shulman
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-19       Impact factor: 5.742

5.  Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease.

Authors:  Sherrie J Divito; Anders T Aasebø; Tiago R Matos; Pei-Chen Hsieh; Matthew Collin; Christopher P Elco; John T O'Malley; Espen S Bækkevold; Henrik Reims; Tobias Gedde-Dahl; Michael Hagerstrom; Jude Hilaire; John W Lian; Edgar L Milford; Geraldine S Pinkus; Vincent T Ho; Robert J Soiffer; Haesook T Kim; Martin C Mihm; Jerome Ritz; Indira Guleria; Corey S Cutler; Rachael A Clark; Frode L Jahnsen; Thomas S Kupper
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

6.  Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

Authors:  Diana M Cardona; Claire J Detweiler; Michael J Shealy; Anthony D Sung; Daniel M Wild; Martin H Poleski; Bryan L Balmadrid; Constance T Cirrincione; David N Howell; Keith M Sullivan
Journal:  Arch Pathol Lab Med       Date:  2018-04-26       Impact factor: 5.534

7.  Apoptosis of ileal crypt epithelia after allogeneic bone marrow transplantation without graft-versus-host disease.

Authors:  Andreas Kreft; Alexandra Russo; Steffi Lux; Lioudmila Waiz; Larissa Seidmann; Jörg Faber; Charles J Kirkpatrick
Journal:  Clin Case Rep       Date:  2015-02-19

8.  Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Fryderyk Lorenz; Stefan Marklund; Mårten Werner; Richard Palmqvist; Björn Engelbrekt Wahlin; Anders Wahlin
Journal:  Sci Rep       Date:  2015-01-21       Impact factor: 4.379

9.  Extracellular Nucleic Acids in Urine: Sources, Structure, Diagnostic Potential.

Authors:  O E Bryzgunova; P P Laktionov
Journal:  Acta Naturae       Date:  2015 Jul-Sep       Impact factor: 1.845

10.  Evaluation of crypt apoptotic bodies and apoptotic indices in pediatric celiac disease by routine staining and H2AX immunostaining.

Authors:  Sarah Adel Hakim; Dalia Abd El-Kareem
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.